title: Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.
abstract: Heregulins (HRGs) are epidermal growth factor (egf) domain containing polypeptide growth factors that bind and activate several members of the ErbB receptor family. Although HRG can bind to ErbB3 and ErbB4 homodimers, the highest affinity and most intracellularly active receptor complexes are hetero-oligomers containing ErbB2. The HRGbeta egf domain was displayed on the surface of M13 phage to facilitate mutagenic analysis and optimize for binding to a homodimeric ErbB3-immunoglobulin (IgG) fusion. Nine libraries were constructed in which virtually the entire sequence was randomized in stretches of four to six amino acids. These were selected separately for binding to immobilized ErbB3-IgG. Analysis of the resulting sequences revealed some areas that diverged radically from the wild-type, whereas others showed strong conservation. The degree of wild-type conservation correlated strongly with the functional importance of the residues as determined by alanine scanning mutagenesis (Jones, J. T., Ballinger, M. D., Pisacane, P. I., Lofgren, J. A., Fitzpatrick, V. D., Fairbrother, W. J., Wells, J. A., and Sliwkowski, M. X. (1998) J. Biol. Chem. 273, 11667-11674). Some variants from several libraries showed significant improvements in binding affinity to the ErbB3-IgG. These optimized segments were combined in various ways in the same molecule to generate variants (containing up to 16 mutations) that had >50-fold higher affinity than wild-type HRGbeta. The optimized variants stimulated ErbB2 phophorylation on MCF7 cells at levels similar to wild-type. This indicates wild-type affinity is optimized for potency and that factors other than affinity for ErbB3 are limiting. These variants showed enhanced affinity toward the ErbB4 homodimer, suggesting these receptors use very similar binding determinants despite them having 65% sequence identity.
authors.affiliation: Department of Protein Engineering, Genentech, Incorporated, South San Francisco, California 94080, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Ballinger
authors.forename: J T
authors.initials: JT
authors.lastname: Jones
authors.forename: J A
authors.initials: JA
authors.lastname: Lofgren
authors.forename: W J
authors.initials: WJ
authors.lastname: Fairbrother
authors.forename: R W
authors.initials: RW
authors.lastname: Akita
authors.forename: M X
authors.initials: MX
authors.lastname: Sliwkowski
authors.forename: J A
authors.initials: JA
authors.lastname: Wells
mesh_terms: D000595:Amino Acid Sequence; D017104:Bacteriophage M13; D001665:Binding Sites; D002352:Carrier Proteins / Q000737:chemistry*; D066246:ErbB Receptors / Q000378:metabolism*; D006023:Glycoproteins / Q000737:chemistry*; D008024:Ligands; D008958:Models, Molecular; D008969:Molecular Sequence Data; D020890:Neuregulin-1; D019906:Nuclear Magnetic Resonance, Biomolecular; D019151:Peptide Library; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D020893:Receptor, ErbB-3; D011994:Recombinant Proteins; D013329:Structure-Activity Relationship
chemical_list: D002352:Carrier Proteins; D006023:Glycoproteins; D008024:Ligands; D020890:Neuregulin-1; D019151:Peptide Library; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins; C087230:heregulin beta1; D066246:ErbB Receptors; D020893:Receptor, ErbB-3